Common Infections — MCQs
On this page
A hospital antimicrobial stewardship team identifies that 55% of surgical prophylaxis for colorectal surgery continues beyond 24 hours post-operatively. Surgical site infection rates are within national benchmarks. Which intervention is most likely to improve compliance with single-dose prophylaxis without increasing infection rates?
A 44-year-old woman with breast cancer receiving chemotherapy (last cycle 8 days ago) presents with fever of 38.9°C and a 2-day history of erythema and tenderness around her Hickman line exit site. Neutrophil count is 0.3 x 10⁹/L. Blood pressure 105/65 mmHg, heart rate 108/min. There is a 4cm area of erythema and purulent discharge at the line site. What is the most appropriate initial antimicrobial management?
A 76-year-old man with type 2 diabetes and peripheral arterial disease presents with a 3-day history of a painful, warm, erythematous area on his shin following minor trauma. Temperature is 37.8°C. There is a 10cm x 8cm area of erythema with a well-demarcated border but no crepitus, blistering, or skin necrosis. CRP 45 mg/L. What is the most appropriate initial management?
According to UK antimicrobial prescribing guidance, which of the following statements about documenting antimicrobial prescriptions is correct?
A 52-year-old woman with community-acquired pneumonia has been receiving intravenous co-amoxiclav for 48 hours. She is now apyrexial, haemodynamically stable, able to eat and drink, and her inflammatory markers are improving (CRP down from 185 to 78 mg/L). Chest examination reveals reduced crackles. What is the most appropriate antimicrobial stewardship action at this stage?
A hospital antimicrobial stewardship committee reviews audit data on community-acquired pneumonia (CAP) management. They find that 78% of patients admitted with low-severity CAP (CURB-65 score 0-1) receive dual antibiotic therapy (amoxicillin plus clarithromycin), while national guidelines recommend monotherapy with amoxicillin for this group unless specific indications exist. When the data is presented to the medical teams, several consultants express concern that monotherapy might miss atypical organisms. What evidence-based response best addresses this concern while supporting antimicrobial stewardship?
A 63-year-old man with type 2 diabetes and end-stage renal failure on haemodialysis three times weekly presents with fever (38.7°C) and a painful, erythematous tunnelled haemodialysis catheter exit site with purulent discharge. Blood cultures drawn from the catheter and peripheral vein both grow Gram-positive cocci in clusters at 14 hours. He is haemodynamically stable. The renal team plans catheter removal and temporary femoral line insertion tomorrow. His last dialysis session was yesterday. What is the most appropriate empirical antimicrobial therapy pending identification and sensitivities?
A 39-year-old woman with well-controlled HIV (CD4 count 520 cells/μL, undetectable viral load on antiretroviral therapy) presents with a 3-day history of a painful, red, swollen area on her right buttock. Examination reveals a 4cm fluctuant, tender swelling consistent with a subcutaneous abscess. Temperature 37.6°C, otherwise systemically well. Incision and drainage is performed in the Emergency Department with good drainage of pus. The sample is sent for culture. What is the most appropriate antimicrobial management following drainage?
A hospital pharmacy department implements a new antimicrobial stewardship intervention requiring pharmacist review and approval for all restricted antibiotics (carbapenems, glycopeptides, anti-pseudomonal agents) within 24 hours of initiation. The pharmacist reviews microbiology results, therapeutic drug monitoring, and can recommend modifications or discontinuation. Which of the following represents the primary mechanism by which this intervention supports antimicrobial stewardship?
A 52-year-old man presents to the Emergency Department with a 2-day history of painful swelling of his left hand following a cat bite 4 days ago. He did not seek initial medical attention. Examination reveals a hot, swollen, tender hand with limited range of movement at the MCP joints and wrist. There is purulent discharge from the bite wound. Temperature 38.1°C, pulse 94 bpm. He has no known drug allergies. Plain radiograph shows no evidence of foreign body or gas in tissues. What is the most appropriate antibiotic regimen?
Common Infections UK Medical PG Practice Questions and MCQs
Question 151: A hospital antimicrobial stewardship team identifies that 55% of surgical prophylaxis for colorectal surgery continues beyond 24 hours post-operatively. Surgical site infection rates are within national benchmarks. Which intervention is most likely to improve compliance with single-dose prophylaxis without increasing infection rates?
- A. Extend prophylaxis to 48 hours for all patients undergoing colorectal surgery
- B. Implement automatic stop orders for surgical prophylaxis at 24 hours post-operatively (Correct Answer)
- C. Require approval from microbiology consultants for prophylaxis continuation
- D. Replace current prophylaxis with broader spectrum agents for longer duration
- E. Provide educational sessions only without changing prescribing systems
Explanation: ***Implement automatic stop orders for surgical prophylaxis at 24 hours post-operatively*** - **Automatic stop orders** are highly effective system-based interventions that reduce unnecessary antibiotic exposure by defaulting to the standard of care. - This approach improves compliance with **prophylaxis guidelines** without requiring individual manual intervention, minimizing the risk of **antimicrobial resistance** and C. difficile infections. *Extend prophylaxis to 48 hours for all patients undergoing colorectal surgery* - Evidence indicates that extending prophylaxis beyond 24 hours does not further reduce **surgical site infection** rates but does increase side effects. - This intervention contradicts the goal of **antimicrobial stewardship** and promotes the development of multi-drug resistant organisms. *Require approval from microbiology consultants for prophylaxis continuation* - While effective for high-cost or broad-spectrum drugs, requiring **consultant approval** for routine prophylaxis creates excessive administrative barriers and delays in care. - This method is less sustainable for high-volume surgical procedures compared to **systemized stop orders**. *Replace current prophylaxis with broader spectrum agents for longer duration* - Increasing the **spectrum of activity** and duration is clinically unnecessary given that infection rates are already within benchmarks. - This strategy would significantly increase **selective pressure** for resistant bacteria without providing additional clinical benefits. *Provide educational sessions only without changing prescribing systems* - Although important, **passive education** alone has been shown to have limited long-term impact on prescribing habits in the absence of **structural changes**. - Educational sessions lack the immediate and reliable impact that **clinical decision support tools** or stop orders provide.
Question 152: A 44-year-old woman with breast cancer receiving chemotherapy (last cycle 8 days ago) presents with fever of 38.9°C and a 2-day history of erythema and tenderness around her Hickman line exit site. Neutrophil count is 0.3 x 10⁹/L. Blood pressure 105/65 mmHg, heart rate 108/min. There is a 4cm area of erythema and purulent discharge at the line site. What is the most appropriate initial antimicrobial management?
- A. Remove line and start IV vancomycin and gentamicin
- B. Take blood cultures via line and peripherally, start IV piperacillin-tazobactam (Correct Answer)
- C. Start oral co-amoxiclav and arrange line removal within 24 hours
- D. Take blood cultures and await results before starting antibiotics
- E. Start IV teicoplanin alone and attempt line salvage
Explanation: ***Take blood cultures via line and peripherally, start IV piperacillin-tazobactam*** - This patient presents with **febrile neutropenia** (neutrophil count 0.3 x 10⁹/L and fever 38.9°C), a medical emergency requiring **immediate broad-spectrum IV antibiotics** (ideally within one hour) to cover both Gram-positive and Gram-negative organisms, such as **piperacillin-tazobactam**. - **Blood cultures** from both the central venous catheter and a peripheral site are crucial to help diagnose a **catheter-related bloodstream infection (CRBSI)** by comparing the differential time to positivity, guiding subsequent management. *Remove line and start IV vancomycin and gentamicin* - While the Hickman line is a likely source of infection and may need removal, **initial management** prioritizes stabilizing the patient with prompt **broad-spectrum IV antibiotics** before definitive line management. - **Gentamicin** provides good Gram-negative coverage but lacks adequate Gram-positive coverage, and combined with vancomycin (primarily Gram-positive), it doesn't offer the immediate broad empirical spectrum, including anti-pseudomonal activity, that a single agent like piperacillin-tazobactam provides for **neutropenic sepsis**. *Start oral co-amoxiclav and arrange line removal within 24 hours* - **Oral antibiotics** are insufficient for managing **febrile neutropenia** with a suspected central line infection and signs of systemic compromise; **IV antimicrobial therapy** is essential for rapid systemic delivery. - Delaying definitive treatment for a procedure like line removal is inappropriate in a rapidly progressing condition like **neutropenic sepsis**; immediate broad-spectrum antibiotics are paramount. *Take blood cultures and await results before starting antibiotics* - Delaying antibiotic administration until **blood culture results** are available is contraindicated in **febrile neutropenia** due to the high risk of rapid clinical deterioration, **septic shock**, and mortality. - **Empiric broad-spectrum antibiotics** must be initiated immediately after blood cultures are drawn, without waiting for pathogen identification or susceptibility results. *Start IV teicoplanin alone and attempt line salvage* - **Teicoplanin** is a glycopeptide that primarily covers **Gram-positive organisms** (including MRSA) but provides no coverage for **Gram-negative bacteria**, which are major pathogens in **neutropenic sepsis**, especially Pseudomonas species. - **Monotherapy** with a glycopeptide is therefore inadequate for initial empiric treatment of **febrile neutropenia**; comprehensive Gram-negative coverage is mandatory, and line salvage attempts are secondary to effective antimicrobial therapy.
Question 153: A 76-year-old man with type 2 diabetes and peripheral arterial disease presents with a 3-day history of a painful, warm, erythematous area on his shin following minor trauma. Temperature is 37.8°C. There is a 10cm x 8cm area of erythema with a well-demarcated border but no crepitus, blistering, or skin necrosis. CRP 45 mg/L. What is the most appropriate initial management?
- A. Oral flucloxacillin 500mg four times daily (Correct Answer)
- B. Oral co-amoxiclav 625mg three times daily
- C. IV flucloxacillin 2g four times daily
- D. Oral doxycycline 200mg loading then 100mg twice daily
- E. Arrange urgent surgical debridement
Explanation: ***Oral flucloxacillin 500mg four times daily*** - This patient presents with **cellulitis**, characterized by a painful, warm, erythematous area with a **well-demarcated border** and mild systemic symptoms (low-grade fever, elevated CRP) but no signs of severe infection. - **Flucloxacillin** is the first-line oral antibiotic for uncomplicated cellulitis, providing effective coverage against the most common causative organisms, **Staphylococcus aureus** and **Streptococci**. *Oral co-amoxiclav 625mg three times daily* - **Co-amoxiclav** offers a broader spectrum of activity, including anaerobes, which is generally not required for typical uncomplicated cellulitis following minor trauma. - It is usually reserved for specific scenarios such as **animal/human bites**, diabetic foot infections, or when polymicrobial infection is highly suspected. *IV flucloxacillin 2g four times daily* - **Intravenous antibiotics** are typically indicated for severe cellulitis (e.g., Eron Class III or IV) with signs of **sepsis**, rapid progression, or inability to tolerate oral medications. - The patient's condition, with only mild fever and no signs of systemic toxicity or rapid spread, allows for **oral antibiotic therapy** as the initial approach. *Oral doxycycline 200mg loading then 100mg twice daily* - **Doxycycline** is primarily used as an alternative agent for cellulitis in patients with a confirmed **penicillin allergy** or when **MRSA** (Methicillin-resistant Staphylococcus aureus) infection is suspected. - Since there is no mention of penicillin allergy or specific risk factors for MRSA, **flucloxacillin** remains the preferred first-line treatment. *Arrange urgent surgical debridement* - **Surgical debridement** is reserved for severe infections like **necrotizing fasciitis**, deep abscesses, or significant tissue necrosis. - The absence of **crepitus**, blistering, or skin necrosis explicitly rules out necrotizing fasciitis in this case, making surgical intervention unnecessary.
Question 154: According to UK antimicrobial prescribing guidance, which of the following statements about documenting antimicrobial prescriptions is correct?
- A. Indication must be documented within 48 hours of starting treatment
- B. Review date is optional for oral antibiotics in primary care
- C. Clinical indication, dose, route and duration/review date must all be documented at time of prescribing (Correct Answer)
- D. Duration can be determined later once microbiological results are available
- E. Only the consultant responsible needs to document the indication in medical notes
Explanation: ***Clinical indication, dose, route and duration/review date must all be documented at time of prescribing*** - According to 'Start Smart - Then Focus' guidelines, this documentation is essential at the **point of prescribing** to ensure patient safety and effective **antimicrobial stewardship**. - Clear documentation allows for **timely clinical review** and prevents unnecessary prolonged courses of antibiotics. *Indication must be documented within 48 hours of starting treatment* - The **clinical indication** must be documented **immediately** when the prescription is written, not delayed by 48 hours. - The **48-72 hour** window is reserved for the **clinical review** and decision to stop, switch, or continue treatment based on culture results. *Review date is optional for oral antibiotics in primary care* - Including a **review date or duration** is a mandatory requirement for all antimicrobial prescriptions to prevent **inappropriate long-term use**. - This applies across all healthcare settings, including **primary care**, to maintain safety and reduce **antibiotic resistance**. *Duration can be determined later once microbiological results are available* - An initial **duration or review date** must be specified at the start of treatment based on **empirical guidelines**. - While treatment may be adjusted after **microbiology results** are available, it cannot be left open-ended at the initial prescribing stage. *Only the consultant responsible needs to document the indication in medical notes* - It is the responsibility of the **individual prescriber**, regardless of grade, to ensure all details are documented correctly in the **medical records**. - **Contemporaneous documentation** by the prescriber ensures that the rationale for therapy is transparent to all members of the multidisciplinary team.
Question 155: A 52-year-old woman with community-acquired pneumonia has been receiving intravenous co-amoxiclav for 48 hours. She is now apyrexial, haemodynamically stable, able to eat and drink, and her inflammatory markers are improving (CRP down from 185 to 78 mg/L). Chest examination reveals reduced crackles. What is the most appropriate antimicrobial stewardship action at this stage?
- A. Continue IV co-amoxiclav for a total of 7 days
- B. Switch to oral co-amoxiclav and consider early discharge (Correct Answer)
- C. Stop antibiotics as she is now clinically improved
- D. Change to oral clarithromycin monotherapy
- E. Continue IV co-amoxiclav for 5 days then switch to oral
Explanation: ***Switch to oral co-amoxiclav and consider early discharge*** - The patient meets criteria for **IV-to-oral switch (IVOS)**, demonstrating **clinical stability** (apyrexial, haemodynamically stable, tolerating oral intake) and **improving inflammatory markers** (CRP decreasing). - This action represents good **antimicrobial stewardship**, minimizing risks associated with intravenous access (e.g., phlebitis, line infections) and facilitating **early hospital discharge**. *Continue IV co-amoxiclav for a total of 7 days* - Continuing intravenous therapy when a patient is clinically stable and able to take oral medication is an example of **over-prescribing IV medications**. - Prolonged IV access increases the risk of **cannula-related complications** and **hospital-acquired infections**, which is contrary to stewardship principles. *Stop antibiotics as she is now clinically improved* - While the patient is improving, stopping antibiotics prematurely can lead to **relapse** of the infection and potentially foster the development of **antibiotic resistance**. - Community-acquired pneumonia typically requires a course of 5-7 days, and 48 hours is usually insufficient for complete **bacterial eradication**. *Change to oral clarithromycin monotherapy* - Switching to a different **antibiotic class** like a macrolide without a specific indication (e.g., proven atypical pathogen, allergy to penicillin) is not appropriate when co-amoxiclav is effective. - This action could broaden the **antibiotic spectrum** unnecessarily or lead to treatment failure if the initial pathogen is not susceptible to clarithromycin. *Continue IV co-amoxiclav for 5 days then switch to oral* - Delaying the switch to oral therapy for an additional 3 days when the patient is already stable and meeting IVOS criteria is **unnecessary intravenous use**. - Antimicrobial stewardship emphasizes transitioning to oral therapy as soon as clinically appropriate to reduce complications and **hospital stay**.
Question 156: A hospital antimicrobial stewardship committee reviews audit data on community-acquired pneumonia (CAP) management. They find that 78% of patients admitted with low-severity CAP (CURB-65 score 0-1) receive dual antibiotic therapy (amoxicillin plus clarithromycin), while national guidelines recommend monotherapy with amoxicillin for this group unless specific indications exist. When the data is presented to the medical teams, several consultants express concern that monotherapy might miss atypical organisms. What evidence-based response best addresses this concern while supporting antimicrobial stewardship?
- A. Agree to continue dual therapy as consultant concerns about clinical risk should take precedence over stewardship guidelines
- B. Present evidence that macrolide addition in low-severity CAP shows no mortality benefit and increases antibiotic exposure and C. difficile risk without clear clinical benefit (Correct Answer)
- C. Propose a compromise of using monotherapy for CURB-65 0 but continuing dual therapy for CURB-65 1 patients
- D. Suggest that all patients should have atypical serology tested on admission to guide whether to add a macrolide
- E. Recommend switching to fluoroquinolone monotherapy (levofloxacin) which covers both typical and atypical organisms
Explanation: ***Present evidence that macrolide addition in low-severity CAP shows no mortality benefit and increases antibiotic exposure and C. difficile risk without clear clinical benefit*** - In patients with **low-severity CAP (CURB-65 0-1)**, randomized trials and meta-analyses demonstrate that **macrolide** addition does not improve outcomes compared to **beta-lactam monotherapy**. - Prioritizing evidence helps address clinician fear while reducing **collateral damage**, such as **C. difficile** risk, adverse drug reactions, and the selection of **resistant organisms**. *Agree to continue dual therapy as consultant concerns about clinical risk should take precedence over stewardship guidelines* - This approach ignores **evidence-based guidelines** and fails to fulfill the primary mission of the **Antimicrobial Stewardship (AMS)** committee. - Deferring to clinical preference without reviewing data leads to **excessive antibiotic use** and does not mitigate the actual risks of antibiotic resistance or side effects. *Propose a compromise of using monotherapy for CURB-65 0 but continuing dual therapy for CURB-65 1 patients* - There is no clinical evidence to support this compromise, as patients with a **CURB-65 score of 1** are still categorized as **low risk** with low mortality. - National guidelines (like **BTS** and **NICE**) consistently recommend **monotherapy** for the entire 0-1 score group unless specific contraindications exist. *Suggest that all patients should have atypical serology tested on admission to guide whether to add a macrolide* - **Atypical serology** is generally not useful for acute management because it often requires **convalescent samples** (taken weeks later) to confirm a diagnosis. - These tests have poor sensitivity and specificity in the acute setting and do not provide the **rapid results** needed to guide initial antibiotic selection. *Recommend switching to fluoroquinolone monotherapy (levofloxacin) which covers both typical and atypical organisms* - This represents unnecessary use of **broad-spectrum** agents, which should be reserved for those with **beta-lactam allergies** or more severe disease. - **Fluoroquinolones** carry significant risks, including **tendon rupture**, QT prolongation, and high associations with **C. difficile** infection.
Question 157: A 63-year-old man with type 2 diabetes and end-stage renal failure on haemodialysis three times weekly presents with fever (38.7°C) and a painful, erythematous tunnelled haemodialysis catheter exit site with purulent discharge. Blood cultures drawn from the catheter and peripheral vein both grow Gram-positive cocci in clusters at 14 hours. He is haemodynamically stable. The renal team plans catheter removal and temporary femoral line insertion tomorrow. His last dialysis session was yesterday. What is the most appropriate empirical antimicrobial therapy pending identification and sensitivities?
- A. Intravenous flucloxacillin 2g four times daily with dose adjustment for renal function
- B. Intravenous vancomycin 15-20mg/kg loading dose, then subsequent dosing guided by levels and dialysis schedule (Correct Answer)
- C. Intravenous teicoplanin 800mg loading dose, then 400mg after each dialysis session
- D. Intravenous daptomycin 6mg/kg after each dialysis session
- E. Oral doxycycline 100mg twice daily as outpatient with catheter left in situ
Explanation: ***Intravenous vancomycin 15-20mg/kg loading dose, then subsequent dosing guided by levels and dialysis schedule*** - This patient presents with a **catheter-related bloodstream infection (CRBSI)**, indicated by the infected catheter exit site and positive blood cultures with **Gram-positive cocci in clusters** in a haemodialysis patient. - **Vancomycin** is the recommended empirical therapy for suspected CRBSI in this population, providing crucial coverage against **MRSA**, and requires a **loading dose** followed by level-guided dosing adjusted for **dialysis**. *Intravenous flucloxacillin 2g four times daily with dose adjustment for renal function* - While effective against **MSSA**, flucloxacillin lacks coverage for **MRSA**, which is a prevalent and serious pathogen in **haemodialysis patients** with catheter infections. - Empirical treatment of CRBSI in this high-risk group mandates coverage for **MRSA** until sensitivities are known, making flucloxacillin insufficient. *Intravenous teicoplanin 800mg loading dose, then 400mg after each dialysis session* - Although **teicoplanin** is effective against **MRSA**, **vancomycin** is often preferred as first-line empirical therapy in CRBSI due to more established dosing protocols and extensive clinical experience in **dialysis patients**. - The suggested maintenance dose may be suboptimal, as ensuring adequate **trough levels** can be challenging, often requiring more aggressive initial dosing strategies for serious infections. *Intravenous daptomycin 6mg/kg after each dialysis session* - **Daptomycin** is typically reserved for specific situations like **vancomycin-resistant organisms** or in cases of glycopeptide intolerance/failure, to preserve its efficacy and prevent resistance. - For a serious **Staphylococcus aureus bacteraemia** in dialysis patients, a higher dose (often 8-10 mg/kg) is usually indicated, making 6 mg/kg potentially **subtherapeutic**. *Oral doxycycline 100mg twice daily as outpatient with catheter left in situ* - **Oral antibiotics** are inappropriate for treating a suspected **bloodstream infection** with systemic signs like fever and purulent discharge from a central venous catheter. - The presence of a **tunnelled catheter infection** with bacteraemia mandates **catheter removal** and inpatient intravenous antimicrobial therapy to prevent severe complications such as **endocarditis**.
Question 158: A 39-year-old woman with well-controlled HIV (CD4 count 520 cells/μL, undetectable viral load on antiretroviral therapy) presents with a 3-day history of a painful, red, swollen area on her right buttock. Examination reveals a 4cm fluctuant, tender swelling consistent with a subcutaneous abscess. Temperature 37.6°C, otherwise systemically well. Incision and drainage is performed in the Emergency Department with good drainage of pus. The sample is sent for culture. What is the most appropriate antimicrobial management following drainage?
- A. Intravenous vancomycin 1g twice daily for 7 days as inpatient due to HIV status
- B. Oral flucloxacillin 1g four times daily for 7 days and outpatient follow-up
- C. No antibiotics; drainage alone is adequate, arrange wound review in 48 hours (Correct Answer)
- D. Oral co-amoxiclav 625mg three times daily for 10 days due to immunosuppression
- E. Oral doxycycline 100mg twice daily for 14 days pending culture results
Explanation: ***No antibiotics; drainage alone is adequate, arrange wound review in 48 hours*** - For a **simple cutaneous abscess**, the definitive treatment is **incision and drainage** (I&D); antibiotics do not improve outcomes in patients without systemic signs or extensive cellulitis. - Despite her HIV status, a **CD4 count >500** and undetectable viral load mean she is managed as an **immunocompetent** host for this minor soft tissue infection. *Intravenous vancomycin 1g twice daily for 7 days as inpatient due to HIV status* - **Inpatient admission** and **intravenous MRSA coverage** are not indicated for an otherwise healthy, systemically well patient with a localized infection. - Vancomycin is reserved for severe infections, suspected **MRSA**, or situations where oral therapy is not feasible. *Oral flucloxacillin 1g four times daily for 7 days and outpatient follow-up* - While flucloxacillin is standard for cellulitis, it is unnecessary here as **source control** (drainage) has already been established and there is no mention of spreading **surrounding cellulitis**. - Routine use of antibiotics for drained abscesses increases the risk of side effects like **C. difficile** and antibiotic resistance. *Oral co-amoxiclav 625mg three times daily for 10 days due to immunosuppression* - **Immunosuppression** is not a mandate for antibiotics if the immune profile (CD4 count) is high and the infection is localized and drained. - **Co-amoxiclav** provides broader coverage than necessary for typical skin flora like *Staphylococcus aureus* or *Streptococcus pyogenes*. *Oral doxycycline 100mg twice daily for 14 days pending culture results* - **Doxycycline** is an alternative for community-acquired MRSA, but antibiotics remain unnecessary since the abscess has been successfully **drained**. - A **14-day course** is excessively long for a simple skin and soft tissue infection that has already received primary surgical management.
Question 159: A hospital pharmacy department implements a new antimicrobial stewardship intervention requiring pharmacist review and approval for all restricted antibiotics (carbapenems, glycopeptides, anti-pseudomonal agents) within 24 hours of initiation. The pharmacist reviews microbiology results, therapeutic drug monitoring, and can recommend modifications or discontinuation. Which of the following represents the primary mechanism by which this intervention supports antimicrobial stewardship?
- A. It creates an administrative barrier that reduces inappropriate initiation of restricted antibiotics
- B. It ensures optimal dosing of expensive antibiotics to reduce pharmacy costs
- C. It provides prospective audit with intervention and feedback to prescribers, enabling targeted therapy optimization (Correct Answer)
- D. It transfers prescribing responsibility from medical staff to pharmacy staff, improving accountability
- E. It standardizes antibiotic prescribing across the hospital by enforcing protocol compliance
Explanation: ***It provides prospective audit with intervention and feedback to prescribers, enabling targeted therapy optimization*** - This intervention represents a core strategy in **antimicrobial stewardship**, where pharmacists review ongoing therapy *after* initiation but *within 24 hours*, providing **prospective audit and feedback**. - The review of **microbiology results** and **therapeutic drug monitoring** enables **targeted therapy optimization**, including de-escalation, dose adjustments, or discontinuation, improving patient outcomes and reducing resistance. *It creates an administrative barrier that reduces inappropriate initiation of restricted antibiotics* - While some **AMS** interventions, like preauthorization, create barriers, this specific model focuses on **post-initiation review** and optimization rather than simply preventing the initial prescription. - The intent is clinical refinement based on evolving data, not solely an administrative deterrent to antibiotic use. *It ensures optimal dosing of expensive antibiotics to reduce pharmacy costs* - **Cost reduction** is a secondary benefit of appropriate antimicrobial use, but the primary mechanism of stewardship is to improve **patient safety** and combat **antimicrobial resistance**. - Emphasizing only cost overlooks the critical clinical and public health goals of **antimicrobial stewardship programs**. *It transfers prescribing responsibility from medical staff to pharmacy staff, improving accountability* - **Antimicrobial stewardship** is a **collaborative process** where pharmacists offer recommendations and expert guidance, but the **prescribing physician** maintains ultimate responsibility for patient care decisions. - The intervention facilitates **interprofessional communication** and shared decision-making rather than a complete transfer of clinical authority. *It standardizes antibiotic prescribing across the hospital by enforcing protocol compliance* - While protocols are valuable, this intervention highlights **individualized patient review** based on specific **microbiology** and **therapeutic drug monitoring**, allowing for tailored therapy. - It moves beyond mere **protocol enforcement** by providing dynamic, patient-specific recommendations that optimize treatment for each unique clinical scenario.
Question 160: A 52-year-old man presents to the Emergency Department with a 2-day history of painful swelling of his left hand following a cat bite 4 days ago. He did not seek initial medical attention. Examination reveals a hot, swollen, tender hand with limited range of movement at the MCP joints and wrist. There is purulent discharge from the bite wound. Temperature 38.1°C, pulse 94 bpm. He has no known drug allergies. Plain radiograph shows no evidence of foreign body or gas in tissues. What is the most appropriate antibiotic regimen?
- A. Oral flucloxacillin 1g four times daily
- B. Intravenous co-amoxiclav 1.2g three times daily (Correct Answer)
- C. Oral doxycycline 100mg twice daily and metronidazole 400mg three times daily
- D. Intravenous ceftriaxone 2g once daily
- E. Oral co-trimoxazole 960mg twice daily
Explanation: ***Intravenous co-amoxiclav 1.2g three times daily*** - **Co-amoxiclav** is the first-line treatment for cat bites because it covers common pathogens like **Pasteurella multocida**, **Staphylococcus aureus**, and anaerobes. - In this case, **intravenous** administration is necessary due to systemic symptoms (fever), purulent discharge, and risk of deep tissue involvement like **septic arthritis** or **tenosynovitis**. *Oral flucloxacillin 1g four times daily* - **Flucloxacillin** is ineffective as a monotherapy for cat bites because it lacks sufficient activity against **Pasteurella multocida**. - Oral therapy is inappropriate here due to the severity of the infection and the patient's **systemic inflammatory response**. *Oral doxycycline 100mg twice daily and metronidazole 400mg three times daily* - This combination is typically reserved for patients with a **penicillin allergy**, which this patient does not have. - Even if used for allergy, the severe clinical presentation and potential **deep space infection** require parenteral (IV) broad-spectrum therapy rather than oral. *Intravenous ceftriaxone 2g once daily* - While **ceftriaxone** provides good coverage for **Pasteurella species**, it does not provide adequate coverage for the **anaerobes** frequently found in feline oral flora. - It is not considered the standard empirical first-line choice compared to the broader coverage offered by **co-amoxiclav**. *Oral co-trimoxazole 960mg twice daily* - **Co-trimoxazole** has unreliable and variable activity against **Pasteurella multocida**, making it an unsafe empirical choice. - It lacks the necessary **anaerobic coverage** and the clinical potency required to treat an established, severe infection in the hand.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free